<DOC>
	<DOC>NCT01713153</DOC>
	<brief_summary>This is a large, community-based, cluster-randomized trial to compare routine prophylactic use of 600 mcg oral misoprostol and 10 IU oxytocin delivered by UnijectTM intramuscularly during the third stage of labor</brief_summary>
	<brief_title>Comparing Misoprostol and Oxytocin in Uniject for Postpartum Hemorrhage (PPH) Prevention in Senegal</brief_title>
	<detailed_description>This study will assess the programmatic implications (including feasibility, acceptability, risks and benefits) at the community level of the introduction of misoprostol and/or oxytocin in UnijectTM for the prevention of PPH and will help to identify the appropriate niche for both drugs.</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>women delivering in community health centers (case de sante) with a trained study provider (matrone) who are able to provide informed consent women with known contraindications to prostaglandins</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>postpartum hemorrhage</keyword>
	<keyword>prevention</keyword>
	<keyword>misoprostol</keyword>
	<keyword>Uniject</keyword>
	<keyword>oxytocin</keyword>
</DOC>